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Abstract
Adipose tissue is a primary site of obesity-induced inflammation, which has been emerging as an important contributor to obesity
associateddisorders.The factors influencingadipose tissue-induced inflammationand the resultingpathophysiological events remain
poorly understood. However, dietary fiber consumptions appear to be protective. Short-chain fatty acids such as propionic acid (PA)
are the principal products of the dietary fiber fermentation by microbiota. Therefore, we aim to investigate the influence of PA on
inflammation, lipogenesis andglucoseuptakemarkers fromhumansubcutaneous adipose tissue (SAT).Weshowed that the treatment
ofSATwithPAresulted ina significantdownregulationof inflammatoryparameters (e.g.TNF-αand IP-10) andmacrophagemarkers
(e.g. CD163 and MMP-9). The expression levels of PA receptors (i.e. G protein coupled receptor-41 and -43) in human primary
adipocyteswerevery lowincomparisonwithSATandmacrophages.UponPAtreatment,noanti-inflammatoryeffectwasobserved in
humanadipocytes.PAsignificantlyupregulated theexpressionof lipoprotein lipase (LPL), sterol regulatory-element-bindingprotein-
1c (SREBP-1c) and glucose transporter 4 (GLUT-4), which are associatedwith lipogenesis and glucose uptake.We also showed that
theobservedanti-inflammatoryeffects ofPAonSATwerepartlymediatedbyGi/oproteincoupled receptor.Ourdata suggests thatPA
anti-inflammatory effects on SATaremediated partly viaGi/o proteins, leading to the improved expression of factors associatedwith
lipogenesis andglucose uptake.These responses appeared to be notmediated by adipocytes; butmost probably bymacrophages. The
current study provides new knowledge, which can be used as a potential new avenue for drug development in preventing obesity-
related inflammation andmetabolic disorders in future.
Keywords Propionic acid . Subcutaneous adipose tissue . Inflammation . Gi/o proteins coupled receptors . IP-10 and TNF-alpha,
macrophage
Introduction
Obesity has reached epidemicproportions and is still escalating
at an alarming rate worldwide. World Health Organization re-
ported that population living on earth is approximately 7.77.7
billion ofwhichmore than 1.9 billion adults (~39%)with over-
weightandover600millionwithobese (~13%)[1]. InPalestine
theprevalenceofobesity has beenshown tobeapproximately4
times among women (49%) and 2 times among men (30%)
higher than the worldwide observed prevalence [2].
Obesity is associated with chronic activation of low-grade
inflammation [3], which is implicated in the pathogenesis of
obesity-associated diseases including insulin resistance, type-2
diabetes (T2D) [4, 5] and cardiovascular disease [6, 7]. The eti-
ology of obesity and low-grade inflammation is complex and
involves intrinsic and extrinsic factors. Recently, it has been
shown that specificmembers ofmicrobiota in humans, in partic-
ular Firmicutes, are associated with obesity and its associated
afflictions [8–11].
Furthermore, thecolonizationofgerm-freemicewithmicro-
biota derived from obese mice results in significantly greater
adiposity than colonization with microbiota from lean mice
[12]. Conversely, prebiotic diets such as fructans [13] are asso-
ciatedwithgeneral better health, including thedecrease in body
weight, fat mass and the severity of T2D [14–16]. The factors
that influence the composition and metabolism of intestinal
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microbiota and obesity and its related inflammation and patho-
physiology remain, however, obscure at best.
Fermentation of dietary fiber/ resistant starch by colonic
microbiota is a primary source for the production of short-
chain fatty acids (SCFAs), in particular acetic, butyric and
propionic acids. It has been demonstrated that SCFAs influ-
ence the physiology of humans such as inhibition of inflam-
mation, protection from cancer and promotion of satiety
[17–20]. Recently it has been shown that mice deficient in G
protein–coupled receptor 43 (GPR43) have exacerbated and
poorly resolving inflammation in animal models of arthritis,
allergic airway inflammation and colitis [21]. Germ-free mice
model of arthritis has also showed increased inflammation and
a much slower resolution of inflammation when compared to
conventionally raised mice. GPCR43 is a receptor of SCFAs
and consequently providing acetate in the drinking water has
reduced inflammation in these mice. Therefore, one could
envisage that SCFAs, including PA, may constitute the elusive
link between the host and microbiota.
Obesity triggers inflammation in Adipose tissue (AT),
which in turn implicated in pathophysiological events such
as T2D. AT is also primary organ involved inobesity [20,
22–25]. In the current study, we determined the anti-
inflammatory effect of PA on SAT and adipocytes [26].
Methods
Materials
Gentamycin, glucose and PA were purchased from Sigma.
M199 media was purchased from Invitrogen. Preadipocytes
and their media were purchased from PromoCell. Cluster of
differentiation 16A (CD16A), Cluster of differentiation 31
(CD31), matrix metalloproteinase 9 (MMP-9), GPCR41 and
GPCR43 primers were purchased from Applied Biosystems.
Human adipose tissue (AT) and cell culture
AT explants were obtained from human subjects who
underwent surgery for disorders. None of the human
subjects had diabetes and the age average was 48, and
Body Mass Index average was 28 kg/m2. This study
was approved by the An-Najah National University,
Institutional Review Board (IRB) (approves, monitors,
and research involving humans) Committee and in-
formed written consent was obtained from all subjects.
AT culture was performed as described previously [26,
27] with slight modifications. After the last washing
step, tissue explants were incubated for 24 h with or
without 3 mM PA. AT explants were pre-incubated
with pertussis toxin (PTX) (100 ng/mL) for 2 h.
Subsequent ly, AT explan ts were t rea ted wi th
PA (3 mM) for 24 h. All tissues were snap frozen
in liquid nitrogen and stored at −80 °C until RNA
isolation. Secretome (Media fraction collected from
cultured tissues) was stored at −80 °C meant for
ELISA and multi ELISA measurements. With respect
to human preadipocytes, they were cultured and dif-
ferentiated into adipocytes according to PromoCell
instructions.
RT-PCR analysis
Total RNA was isolated by the RNeasy lipid tissue mini kit
and cDNAwas synthesized using the Quantitect kit (Qiagen).
Relative quantification of genes was performed in triplicates
as described earlier [26, 27]. Briefly, the primers’ pairs and
probes used in this study are displayed in Table 1. Stability of
several housekeeping genes was assessed by geNorm analysis
software (http://medgen.ugent.be/~jvdesomp/genorm/) [28].
GAPDH was chosen as the most stable housekeeping gene
expressed in AT.
The analysis of chemokines and cytokines proteins
in secreted fraction
Secreted chemokines and cytokines were measured in culture
media by multiplex-ELISA assay according to the manufac-
turer’s instructions (Bio-Rad).
Statistics
Comparison between two groups was performed by two-sided
paired Student’s t test, while the rest were analyzed via either
one- or two-ways ANOVA. Results were considered to be
statistically significant at P< 0.05.
Results
Propionic Acid (PA) effect on inflammation in human
subcutaneous adipose tissue (SAT)
Human SAT explants were derived from 10 women. The av-
erages of their BMI, WHR, WC and age were approximately
28, 0.84, 86 and 48 respectively. As demonstrated in Fig. 1,
PA treatment significantly downregulated the secretion of tu-
mor necrosis factor-α (TNF-α) and interferon-gamma-
induced protein (IP-10) by approximately 30%. On the con-
trary, the expression of Macrophage Inflammatory Proteins-
1α and -1β (MIP-1α and MIP-1β), Regulated on Activation
Normal T Cell Expressed and Secreted (RANTES), interleu-
kins (IL-1β, IL-4, IL-10) were remained unchanged upon the
PA stimulation. Il-12 and 13 were not detected in human SAT.
In adipocytes the secretion of TNF-α, IP-10, MIP-1α, MIP-
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1β, IL-1β, IL-4, IL-10, IL-12 and IL-13 was not detected and
monocyte chemoattractant protein-1 (MCP-1) was not affect-
ed. Whereas and unexpectedly, RANTES was increased ap-
proximately by 3 folds after PA treatment (Fig. 2).
Propionic Acid (PA) inhibited the expression
of adipose tissue macrophage (ATM) markers
PA inhibited mRNA expression of ATM markers; CD163,
MMP-9 and CD16A in SAT by approximately 40%, 52% and
25%respectively,while it hadnoeffect onCD31mRNAexpres-
sion as depicted in Fig. 3.
The comparison of ATM markers expression
levels between omental adipose tissue (OAT),
subcutaneous adipose tissue (SAT)
and adipocytes
mRNA levels of CD163, CD31 andMMP-9 in OATwere sig-
nificantly 3201-, 9857- and 8553-folds higher than in human
adipocytes, respectively. Whereas CD16 was not detected in
adipocytes. As compared to SAT, MMP-9 mRNA levels were
found to be approximately 50% higher in OAT; But there were
nosignificantdifferencesbetweenOATandSATwithrespect to
CD163, CD16 and CD31mRNA levels (Fig. 4).
Comparison of GPCR 41 and 43 expression
levels between SAT, adipocytes
and macrophages
As shown in Fig. 5, mRNA level of PA receptor GPCR41 was
significantly higher in SAT than in adipocytes and macro-
phages by 125- and 4-folds respectively. The quantity of
GPCR43 in SATwas similar to the quantity expressed in mac-
rophages; however, it was tremendously lower in adipocytes
(~1050-folds).
Propionic acid positively affects key
metabolic genes in human adipose tissue
explants
As we observed above, PA had anti-inflammatory effect on
the AT. To investigate whether anti-inflammatory effect of PA
negatively influences the associated-markers of metabolic
syndrome, such as lipogenesis and insulin sensitivity, we in-
cubated SAT explants with or without PA in triplicates. As
shown in Fig. 6, the lipoprotein lipase (LPL), sterol
regulatory-element-binding protein-1c (SREBP-1c) and glu-
cose transporter 4 (GLUT-4) mRNA levels were highly up-
regulated in all explants upon PA treatment by approximately
72%, 41% and 42% respectively (Fig. 6).
Table 1 The sequences of the
primers Primer ID Primer sequence (5′➔3′)
GAPDH forward GGT GAA GGT CGG AGT CAA CG
GAPDH reverse ACC ATG TAG TTG AGG TCA ATG AAG G
GAPDH probe CGC CTG GTC ACC AGG GCT GC
GLUT4 forward GCT GTG GCT GGT TTC TCC AA
GLUT4 reverse CCC ATA GCC TCC GCA ACATA
GLUT4 probe CGA GCA ACT TCATCATTG GCATGG GTT
LPL forward TGG AGATGT GGA CCA GCTAGT G
LPL reverse CAG AGA GTC GAT GAA GAG ATG AAT G
LPL probe CTC CCA CGA GCG CT
SREBP1c forward GGATTG CAC TTT CGA AGA CAT G
SREBP1c reverse AGC ATA GGG TGG GTC AAATAG G
SREBP1c probe CAG CTTATC AAC AAC CAA GAC AGT GAC TTC CC
CD163 forward TGC AGA AAA CCC CAC AAA AAG
CD163 reverse CAA GGATCC CGA CTG CAATAA
CD163 probe AAC AGG TCG CTC ATG CCG TCA GTC A
CD16 Hs01569121_m1*
CD31 Hs01065282_m1*
MMP-9 Hs00234579_m1*
GPCR41 Hs00271131_s1*
GPCR43 Hs00271142_s1*
*, ID numbers of primer sets from Applied Biosystems
DARU J Pharm Sci
TN F -
C P A
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
R
Q
IP -1 0
C P A
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
R
Q
R A N TE S
C P A
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
R
Q
M IP -1
C P A
0 .0
0 .5
1 .0
1 .5
R
Q
M IP -1
C P A
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
R
Q
G -C S F
C P A
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
1 .2 5
R
Q
IL -1 0
C P A
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
1 .2 5
R
Q
IL -4
C P A
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
R
Q
***
**
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Gi/o-protein coupled receptors role
in the anti-inflammatory effect of PA
PA is a ligand of both GPCR41 and GPCR43, which both
activate Gi/o-proteins to prime PA signaling [26–28]. To de-
termine the role of Gi/o pathway in the response of inflamma-
tory markers to PA treatment in SAT the SAT biopsies were
pretreated with PTX for 2 h to block the Gi/o pathway and
they were subsequently treated with or without 3 mM PA for
24 h. As displayed in Fig. 7, the inhibition of TNF-α release
by PAwas completely abolished by PTX pretreatment, while
the PA-induced reduction in IP-10, CD163 and MMP-9 ex-
pression was not affected by PTX.
Discussion
SCFAs are mainly metabolites of gut microbiota fermentation
of escaped undigested food. A numerous of studies has been
shown that SCFAs inhibit inflammation with focus on buty-
rate and to a lesser extent on acetate and PA, [16]. In our
previous study we have shown that PA has anti-
inflammatory properties in OAT [26, 27]. The anti-
inflammatory properties of PA were confirmed by showing
that the mice remain lean even when put on a high-fat diet
in mice overexpressing PA receptor (GPR43) specifically in
OAT.Moreover, these mice exhibit a decrease ofmacrophages
and hallmarks of inflammatory [29]. However, PA effect on
human SAT has not (to our knowledge) been investigated.
Furthermore, it is known that OAT and SAT are different
[30] with respect to inflammation. To this end, these studies
showed that OAT releases more pro-inflammatory and less
anti-inflammatory components than SAT [30, 31]. These all
promoted us to investigate the effect of PA on inflammation
in human SAT, lipogenesis and glucose uptake.
Accumulating evidence shows that AT is considered as one
of the major sites of low grade inflammation in obese subjects
[23–25], which contributes to obesity associated energy met-
abolic disorders such as type 2 diabetes (T2D) and cardiovas-
cular diseases (CVDs) [4–7]. In the present study we have
shown that PA inhibits the secretion of certain pro-
inflammatory markers in human SAT. This is in agreement
to PA effect on OAT [26], but to a lesser extent. Notably, this
is in accordance with our earlier finding that PA inhibits
resistin (a pro-inflammatory parameter) protein release and
mRNA expression in both OAT and SAT [27]. Although It
is well suggested that obesity is associated with increased
infiltration of macrophages into human AT [32], which are
identified via specific ATM markers, AT also contains itself
macrophages. In the current study, it has been shown that
Fig. 2 The effect of Propionic Acid (PA) on the secretion of chemokines
and cytokines by human adipocytes. Adipocytes incubated in triplicate
with or without 3 mMPA for 24 h. Secreted quantities of chemokines and
cytokine in the media were determined by multiplex-ELISA. Only
RANTES and MCP-1 were detected and the rest weren’t. Results are
expressed as relative quantities (RQ) compared to the control (without
PA; C). *, P < 0.05 vs. control (without PA; C). M, mean
Fig. 3 The effect of propionic Acid (PA) on the mRNA expression of
adipose tissue macrophage (ATM) related markers. Human subcutaneous
adipose tissue (SAT) explants of each subject were incubated in triplicate
with or without 3 mM PA for 24 h. PA downregulated all of the ATM
markers, i.e. CD16, CD163 and MMP-9. The mRNA expression levels
were determined by RT-PCR and expressed as relative quantities (RQ)
and compared to the control (without PA; C). (N = 10) *, P < 0.05 vs.
control (without PA; C). M, mean
Fig. 1 The influence of Propionic Acid (PA) on the secretion of
chemokines and cytokines by subcutaneous adipose tissue (SAT). SAT
explants of each subject were incubated in triplicate with or without 3mM
PA for 24 h. Secreted quantities of chemokines and cytokine in the media
were determined by multiplex-ELISA. Results are expressed as relative
quantities (RQ) and compared to the control (without PA; C). (N = 10).
**, P < 0.01, ***, P < 0.001 vs. control (without PA; C). M, mean
DARU J Pharm Sci
PA has a great impact on ATM markers supporting the fact
that PA has anti-inflammatory properties.
Most of the examined pro-inflammatory markers were not
detected in the secretome of adipocytes, while the detected
ones were not decreased in response to PA treatment. This
may be due to a very low expression level of PA receptors
GPCR-41 and -43 in adipocytes as compared to macrophages
and SAT. Taking these all together, it implies that non-
adipocyte cells, most likely macrophages, respond to the
anti-inflammatory effect of PA.
The anti-inflammatory properties of PA are associated with
other major metabolic pathways in AT, namely lipogenesis
and glucose metabolism. We have found that both LPL and
GLUT4 expression was up-regulated by PA. Expression of
LPL and GLUT4 is known to be regulated by SREBP1c
[33, 34]. Indeed, we have found an increased SREBP1c ex-
pression upon PA stimulation, suggesting that SREBP1c is
responsible for the increased expression of LPL and
GLUT4. These data also suggest that PA has not only an
anti-inflammatory effect but also PA could have an anabolic
effect similar to insulin, inducing two important metabolic
pathways that are also stimulated by insulin. This is in
Fig. 4 Comparing mRNA
expression of adipose tissue
macrophage (AMT) markers pro-
duced in omental adipose tissue
(OAT), SAT and adipocytes.
mRNAwas isolated from un-
treated explants and adipocytes in
triplicate. mRNA expression
levels were determined by RT-
PCR and expressed as relative
quantities (RQ) compared to the
control (OAT). (N = 10). *,
P < 0.05, ***, P < 0.001 vs. OAT.
M, mean
Fig. 6 The role of Propionic Acid (PA) on the mRNA expression of
lipogenesis and insulin sensitivity related markers. Human subcutaneous
adipose tissue (SAT) explants of each subject were incubated in triplicate
with or without 3 mM PA for 24 h. PA upregulated the expression of
lipoprotein lipase (LPL), SREBP-1c and GLUT-4. The mRNA
expression levels were determined by RT-PCR and shown as relative
quantities (RQ) compared to the control (without PA; C). (N = 10). *,
P < 0.05, **, P < 0.01, ***, P < 0.001 vs. control (without PA; C). M,
mean
Fig. 5 Comparing mRNA levels of GPCR41 and 43 produced in human
subcutaneous adipose tissue (SAT), adipocytes and macrophages. mRNA
was isolated from untreated explants and adipocytes in triplicate. mRNA
expression levels were determined by RT-PCR and shown as relative
quantities (RQ) compared to the control (SAT). (N = 10). *, P < 0.05 vs.
SAT. M, mean
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accordance with the response of OAT to PA in our previous
studies [16, 26, 35] and to the other studies where SCFAs have
been found to increase insulin sensitivity [35].
The expression of the two receptors, GPRC41 and GPRC43,
of PA in human AT (36), suggesting that the effects of PA on the
ATmight be mediated by these receptors. It has been shown that
there is a unique Gi/o coupling for GPCR41, but a dual coupling
exists through Gi/o and Gq proteins for GPCR43, [36]. In this
study we have found that TNF-α response to PA is via Gi/o
protein, suggesting that anti-inflammatory effects of PAmediated
by G protein coupled receptors, while IP-10, CD163 and MMP-
9 response was not mediated via Gi/o pathway. These results are
in line with our earlier study [26], suggesting that both SAT and
OAT employ a similar pathway (i.e. Gi/o protein coupled recep-
tor pathway). However, our findings do not exclude the role of
other pathways, such as Gq proteins and PPARγ. Therefore,
further investigations are needed to dissect the underlying mo-
lecular pathway(s).
Notably, PA exhibits anti-inflammatory effects on human
SAT, which is accompanied by improved expression of pa-
rameters associated with lipogenesis and glucose uptake. We
also demonstrate that anti-inflammatory effects are
parttially mediated by Gi/o proteins and most probably
via macrophages. This finding is similar to our results what
we have observed in OAT in our previous study [26, 37, 38].
The present study provides a new paradigm to understand the
relationship between the microbiota and AT’s physiology and
its potential power in preventing obesity-related inflammation
and energy metabolic disorders. The PA anti-inflammatory
properties on macrophages, the role of GPCR41 and
GPCR43 receptors and other potential underlying mecha-
nisms such as PPARγ remains to be elucidated.
These studies help us to understand better pathways in-
volved in inflammation in ATs and macrophages for drug
research and development.
Compliance with ethical standards
Conflict of interest The authors have declared that no conflict of interest
exists.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. W.H.O. Obesity and overweight fact sheets 2014; Available from:
http://www.who.int/mediacentre/factsheets/fs311/en/
2. Abdul-Rahim HF, Holmboe-Ottesen G, Stene LCM, Husseini A,
Giacaman R, Jervell J, et al. Obesity in a rural and an urban
Fig. 7 Involvement of G protein
coupled receptor(s). The
involvement of Gi/o coupled re-
ceptors in mediating Propionic
Acid (PA) effects on adipokines
expression was determined by
blocking the Gi /o signaling
pathway with pertussis toxin
(PTX). Human subcutaneous adi-
pose tissue (SAT) explants of each
subject were incubated in tripli-
cate with PTX (100 ng / ml) for
2 h before incubation for 24 h
with or without 3 mM PA. Protein
(TNF-α and IP-10) and mRNA
expression (CD163 and MMP-9)
levels were determined using
ELISA and RT-PCR respectively.
Results were depicted as relative
quantities compared with controls
(without PA). (N = 5). **,
P < 0.01, ***, P < 0.001 vs. con-
trol (without PA; C). M, mean
DARU J Pharm Sci
Palestinian West Bank population. Int J Obes Relat Metab Disord.
2003;27(1):140–6.
3. Festa A, D'Agostino Jr R, Williams K, Karter AJ, Mayer-Davis EJ,
Tracy RP, et al. The relation of body fat mass and distribution to
markers of chronic inflammation. Int J Obes Relat Metab Disord.
2001;25(10):1407–15.
4. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J
Clin Invest. 2005;115(5):1111–9.
5. RahimiM, VinciguerraM, DaghighiM, Özcan B, Akbarkhanzadeh
V, Sheedfar F, et al. Age-related obesity and type 2 diabetes
dysregulate neuronal associated genes and proteins in humans.
Oncotarget. 2015;6(30):18–32.
6. Hansson GK. Inflammation, atherosclerosis, and coronary artery
disease. N Engl J Med. 2005;352(16):1685–95.
7. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obe-
sity with cardiovascular disease. Nature. 2006;444(7121):875–80.
8. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD,
Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad
Sci U S A. 2005;102(31):11070–5.
9. Jazayeri O, Daghighi SM, Rezaee F. Lifestyle alters GUT-bacteria
function: linking immune response and host. Best Pract Res Clin
Gastroenterol. 2017;31(6):625–35.
10. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al.
The gut microbiota as an environmental factor that regulates fat
storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23.
11. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D,
et al.Metabolic endotoxemia initiates obesity and insulin resistance.
Diabetes. 2007;56(7):1761–72.
12. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER,
Gordon JI. An obesity-associated gut microbiome with increased
capacity for energy harvest. Nature. 2006;444(7122):1027–31.
13. Ritsema T, Smeekens S. Fructans: beneficial for plants and humans.
Curr Opin Plant Biol. 2003;6(3):223–30.
14. Cani PD, Joly E, Horsmans Y, Delzenne NM. Oligofructose pro-
motes satiety in healthy human: a pilot study. Eur J Clin Nutr.
2006;60(5):567–72.
15. Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM,
Burcelin R. Improvement of glucose tolerance and hepatic insulin
sensitivity by oligofructose requires a functional glucagon-like pep-
tide 1 receptor. Diabetes. 2006;55(5):1484–90.
16. Keenan MJ, Zhou J, McCutcheon KL, Raggio AM, Bateman HG,
Todd E, et al. Effects of resistant starch, a non-digestible ferment-
able fiber, on reducing body fat. Obesity (Silver Spring).
2006;14(9):1523–34.
17. Wong JM, et al. Colonic health: fermentation and short chain fatty
acids. J Clin Gastroenterol. 2006;40(3):235–43.
18. Cook SI, Sellin JH. Review article: short chain fatty acids in health
and disease. Aliment Pharmacol Ther. 1998;12(6):499–507.
19. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ,
Brummer RJ. Review article: the role of butyrate on colonic func-
tion. Aliment Pharmacol Ther. 2008;27(2):104–19.
20. Rezaee F, Dashty M. Role of adipose tissue in metabolic system
disorders: adipose tissue is the initiator of metabolic diseases.
Journal of diabetes and metabolism. J. Diabetes Metab. 2013;S13.
21. Al-Lahham SH, et al. Biological effects of propionic acid in
humans; metabolism, potential applications and underlying mech-
anisms. Biochim Biophys Acta. 2010;1801(11):1175–83.
22. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, di Yu, et al.
Regulation of inflammatory responses by gut microbiota and
chemoattractant receptor GPR43. Nature. 2009;461(7268):1282–6.
23. Trayhurn P,Wood IS. Adipokines: inflammation and the pleiotropic
role of white adipose tissue. Br J Nutr. 2004;92(3):347–55.
24. Skopkova M, et al. Protein array reveals differentially expressed
proteins in subcutaneous adipose tissue in obesity. Obesity (Silver
Spring). 2007;15(10):2396–406.
25. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regula-
tor of inflammation. Best Pract Res Clin Endocrinol Metab.
2005;19(4):547–66.
26. Al-Lahham S, et al. Propionic acid affects immune status and me-
tabolism in adipose tissue from overweight subjects. Eur J Clin
Investig. 2012;42(4):357–64.
27. Al-Lahham SH, et al. Regulation of adipokine production in human
adipose tissue by propionic acid. Eur J Clin Investig. 2010;40(5):
401–7.
28. Vandesompele J, et al. Accurate normalization of real-time quanti-
tative RT-PCR data by geometric averaging of multiple internal
control genes. Genome Biol. 2002;3(7) p. RESEARCH0034.
29. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T,
et al. The gut microbiota suppresses insulin-mediated fat accumu-
lation via the short-chain fatty acid receptor GPR43. Nat Commun.
2013;4:1829.
30. Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication
of depot differences in adipose tissue for obesity complications.
Mol Asp Med. 2013;34(1):1–11.
31. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte
chemoattractant protein-1 release is higher in visceral than subcu-
taneous human adipose tissue (AT): implication of macrophages
resident in the AT. J Clin Endocrinol Metab. 2005;90(4):2282–9.
32. Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R,
et al. From blood monocytes to adipose tissue-resident macro-
phages: induction of diapedesis by human mature adipocytes.
Diabetes. 2004;53(5):1285–92.
33. Im SS, Kwon SK, Kang SY, Kim TH, Kim HI, Hur MW, et al.
Regulation of GLUT4 gene expression by SREBP-1c in adipo-
cytes. Biochem J. 2006;399(1):131–9.
34. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte dif-
ferentiation and gene expression linked to fatty acid metabolism.
Genes Dev. 1996;10(9):1096–107.
35. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in con-
trol of body weight and insulin sensitivity. Nat Rev Endocrinol.
2015;11(10):577–91.
36. Le Poul E, et al. Functional characterization of human receptors for
short chain fatty acids and their role in polymorphonuclear cell
activation. J Biol Chem. 2003;278(28):29481–9.
37. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L,
Daniels D, et al. The orphan G protein-coupled receptors GPR41
and GPR43 are activated by propionate and other short chain car-
boxylic acids. J Biol Chem. 2003;278(13):11312–9.
38. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free
fatty acid receptor, FFA2R, expressed on leukocytes and activated
by short-chain fatty acids. Biochem Biophys Res Commun.
2003;303(4):1047–52.
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
DARU J Pharm Sci
